article Open AccessTop 1% cited

Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide

Arthritis & Rheumatism · 2002 · Vol. 46(8) · pp. 2121–2131

Frédéric Houssiau✉(UCLouvain)Carlos Vasconcelos(Hospital de Santo António)David D’Cruz(Royal London Hospital)Gian Domenico Sebastiani(Ospedale generale di zona San Camillo Treviso)Enrique de Ramón Garrido(Hospital Regional Universitario de Málaga)Maria Giovanna Danieli(Ospedali Riuniti di Ancona)Daniel Abramovicz(Université Libre de Bruxelles)Daniël Blockmans(KU Leuven)Alessandro Mathieu(University of Cagliari)Haner Di̇reskeneli̇(Marmara University)Mauro Galeazzi(University of Siena)Ahmet Gül(Istanbul University)Yair Levy(Tel Aviv University)P Petera(Klinik Hietzing)Rajko Popović(Military Medical Academy)Radmila Petrović(University of Belgrade)Renato Alberto Sinico(Ospedale San Carlo)Roberto Cattaneo(University of Brescia)Josep Font(Universitat de Barcelona)Geneviève Depresseux(Cliniques Universitaires Saint-Luc)Jean‐Pierre Cosyns(UCLouvain)Ricard Cervera(Universitat de Barcelona)

View via DOI Full-text PDF

Abstract

The data from the ELNT indicate that in European SLE patients with proliferative lupus nephritis, a remission-inducing regimen of low-dose IV CYC (cumulative dose 3 gm) followed by AZA achieves clinical results comparable to those obtained with a high-dose regimen.

Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies Autoimmune and Inflammatory Disorders ResearchMedicineLupus nephritisCyclophosphamideRegimenInternal medicineGastroenterologyAzathioprineRandomized controlled trialSystemic lupus erythematosusUrology

MeSH terms

AdolescentAdultAgedAzathioprineCyclophosphamideDose-Response Relationship, DrugFemaleHumansImmunosuppressive AgentsInjections, IntravenousKidney Function TestsLupus NephritisMaleMiddle AgedRemission Induction